Archives: “Archives”

A Novel Skin-Based Approach to Treat Lupus Nephritis

Repurposing topical MC903, an FDA-approved vitamin D analog, to trigger skin-derived bile acid synthesis and generate systemic anti-inflammatory effects in lupus nephritis.

In Vivo Target Identification and Machine Learning Validation of Autoimmune T Cell Tissue Residence

Identifying GSPT1 as an essential, targetable vulnerability of skin-resident memory T cells to enable durable remission in chronic inflammatory skin diseases without systemic immunosuppression.

High-Throughput Center for AutoImmune Therapeutic Discovery (HIT-AI)

Systematically identifying and validating repurposed FDA-approved drugs for over 160 autoimmune diseases using AI, knowledge graphs, and high-throughput experimental screening.

Safety and tolerability of conversion to siponimod from other disease-modifying therapies in patients with advancing forms of relapsing MS: Results from the EXCHANGE study

Sclerotic GVHD and scleroderma share dysregulated gene expression that is ameliorated by EREG therapeutic antibody

Crizanlizumab for retinal vasculopathy with cerebral leukoencephalopathy in a phase II clinical study

Expert perspective: diagnosis and treatment of Castleman disease

A lupus-derived autoantibody that binds to intracellular RNA activates cGAS-mediated tumor immunity and can deliver RNA into cells

A retrospective evaluation of glucagon-like peptide-1 receptor agonists in systemic lupus erythematosus patients

Inside the 2025 Colton Consortium Symposium: Driving Translational Research in Autoimmune Disease

Global leaders in autoimmune research gathered for the 2025 Colton Consortium Symposium last month, sharing breakthroughs from foundational science to translational therapies and forging collaborations to improve patient lives worldwide.